Brands of Sodium Fusidate in Kenya
Fucidin, LEO Pharma A/S
Mode of Action:
Fusidic acid inhibits bacterial protein synthesis by interfering with amino acid transfer from aminoacyl-tRNA to protein on the ribosomes.
Sodium Fusidate is indicated in the treatment of all staphylococcal infections due to susceptible organisms such as: cutaneous infections, osteomyelitis, pneumonia, septicaemia, wound infections, endocarditis, superinfected cystic fibrosis.
Sodium Fusidate should be administered intravenously whenever oral therapy is inappropriate, which includes cases where absorption from the gastro-intestinal tract is unpredictable.
For staphylococcal cutaneous infections:
Standard dose: 250 mg sodium fusidate (equivalent to 240 mg fusidic acid) twice daily for 5-10 days.
For staphylococcal infections such as osteomyelitis, pneumonia, septicaemia, wound infections, endocarditis, superinfected cystic fibrosis.
Standard dose: 500 mg sodium fusidate (equivalent to 480 mg fusidic acid) 3 times daily.
In severe cases of fulminating infections, the dosage may be doubled or appropriate combined therapy may be used.
Elderly: No dosage alterations are necessary in the elderly.
Since Sodium Fusidate is excreted in the bile, no dosage modifications are needed in renal impairment.
The dosage in patients undergoing haemodialysis needs no adjustment as Sodium Fusidate is not significantly dialysed.
- Systemic Sodium Fusidate administered concomitantly with oral anticoagulants such as coumarin derivatives or anticoagulants with similar actions may increase the plasma concentration of these agents enhancing the anticoagulant effect.
- The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic Sodium Fusidate with statins. Co-administration of this combination may cause increased plasma concentrations of both agents.
- Co-administration of systemic Sodium Fusidate and HIV protease inhibitors such as ritonavir and saquinavir may cause increased plasma concentrations of both agents which may result in hepatotoxicity.
ADVERSE DRUG REACTIONS:
The most frequently reported undesirable effects of Sodium Fusidate administered orally are gastrointestinal disorders like abdominal discomfort and pain, diarrhoea, dyspepsia, nausea and vomiting. Anaphylactic shock has been reported.
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, firstname.lastname@example.org or clicking below button:
You can get Sodium fusidate Tablets,Cream or ointment in Registered Pharmacy new You
Sodium Fusidate in Kenya
Sodium Fusidate tablets in Kenya
Sodium Fusidate cost/ price in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: Not available
Routes of Administration: Oral
Bioavailability: 91% oral bioavailability
Protein Binding: 97 to 99%
Metabolosim: Not Available
Onset of Action: Not Available
Elimination Half life: Approximately 5 to 6 hours in adults
Excretion: Not Available
Legal Status | Dosage forms & Strengths
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
|CompTox Dashboard (EPA)|
- Garske, L. A., et al. “Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.” Journal of Hospital Infection 56.3 (2004): 208-214.
- Moriarty SR, Clark K, Scott D, Degenhardt TP, Fernandes P, Craft JC, Corey GR, Still JG and Das A (2010). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract L1-1762